Telitacicept Efficacious, Safe in Treating Rheumatoid Arthritis Patients With Inadequate MTX Response

In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in American College of Rheumatology-20 (ACR20), ACR50, and Disease Activity Score in 28 joints with Erythrocyte Sedimentation Rate responses.

Related Keywords

San Diego ,California ,United States ,Pennsylvania ,Remegen Biosciences ,Qing Zuraw ,American College Of Rheumatology ,American College ,Prescription Pad ,Disease Activity Score ,Erythrocyte Sedimentation Rate ,Total Sharp Score ,Autoimmune ,Rheumatoid Arthritis ,Arthritis ,Nra ,